MYOV earnings

BASEL, Switzerland, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE:MYOV) ("Myovant") today announced the cancellation of its earnings conference call for the quarter ended September 30, 2022 that had originally been scheduled for October 26, 2022 at 5:00 p.m. Eastern Time. The call is being cancelled due to the announcement of the pending merger with Sumitovant Biopharma Ltd. ABOUT MYOVANT SCIENCES Myovant Sciences aspires to redefine care for women and men through purpose-driven science, empowering medicines, and transformative advocacy worldwide. Founded in 2016, Myovant has executed five successful Phase 3 clinical trials across hormone-sensitive oncology and women's health

BASEL, Switzerland, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), today announced it will host a webcast and conference call to discuss corporate updates and financial results for its second fiscal quarter, ended September 30, 2022. The webcast and conference call will be held at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on October 26, 2022. Investors and the general public may access the live webcast here. The live webcast can also be accessed by visiting the company's investor relations page of Myovant's website at: https://investors.myovant.com/. The webcast will be archived on the company website for approximately one year. ABOUT MYOVANT SCIENCES Myova

Data from the Phase 3 SPIRIT program showed MYFEMBREE reduced menstrual pain and non-menstrual pelvic pain in premenopausal women with endometriosis, and a loss of mean bone mineral density of less than 1% from baseline through one year of treatment Myovant and Pfizer will continue to jointly commercialize MYFEMBREE, with product available immediatelyMyovant to host conference call and webcast on Monday, August 8, 2022, at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time BASEL, Switzerland and NEW YORK, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE:MYOV) and Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved MYFEMBREE® (relugolix

First fiscal quarter 2022 total revenue of $116.5 million, including net product revenue of $41.4 million Net product revenue from U.S. sales of ORGOVYX® of $36.0 million in first fiscal quarter 2022, with sequential quarterly demand volume growth of 26% and cumulative patients estimated at 18,000 through June 2022Net product revenue from U.S. sales of MYFEMBREE® of $4.0 million in first fiscal quarter 2022, with sequential quarterly demand volume growth of 54%MYFEMBREE remains the number one prescribed FDA-approved gonadotropin-releasing hormone (GnRH) antagonist therapy for the treatment of uterine fibroids for new patients and is now the market leader in total prescriptions (TRx) with 51

BASEL, Switzerland, July 13, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), today announced it will host a webcast and conference call to discuss corporate updates and financial results for its first fiscal quarter, ended June 30, 2022. The webcast and conference call will be held at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on July 27, 2022. Investors and the general public may access the live webcast here. The live webcast can also be accessed by visiting the company's investor relations page of Myovant's website at: https://investors.myovant.com/. The webcast will be archived on the company website for approximately one year. ABOUT MYOVANT SCIENCES Myovant

Fiscal year 2021 total revenue of $231.0 million, including net product revenues of $94.3 million; fourth fiscal quarter 2021 total revenues of $57.6 million, including net product revenue of $32.4 millionEuropean Commission approval of ORGOVYX® as the first and only oral androgen deprivation therapy for advanced hormone-sensitive prostate cancer in Europe in April 2022Announced exclusive license agreement with Accord Healthcare, Ltd. (Accord) to commercialize ORGOVYX in Europe; total deal value up to $140.5 million, inclusive of upfront payment of $50.0 million, plus tiered royaltiesNet product revenue from U.S. sales of ORGOVYX of $83.0 million in fiscal year 2021; fourth fiscal quarter 20

BASEL, Switzerland, April 26, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) today announced it will host a webcast and conference call to discuss corporate updates and financial results for its fourth fiscal quarter and fiscal year 2021, ended March 31, 2022. The webcast and conference call will be held at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time on May 10, 2022. Investors and the general public may access a live webcast of the call by visiting the investor relations page of Myovant's website at https://investors.myovant.com/. Institutional investors and analysts may also participate in the conference call by dialing 1-800-891-3840 in the U.S. or +1-785-424-1677 from outsi

Third fiscal quarter 2021 total revenues of $54.4 million, including net product revenue of $29.3 millionNet product revenue from U.S. sales of ORGOVYX® of $24.4 million, reflecting 40% sequential volume growth compared to second fiscal quarter 2021, partially offset by a lower net priceNet product revenue from U.S. sales of MYFEMBREE® of $2.4 million; New-to-brand prescription (NBRx) share among GnRH antagonist therapies FDA-approved for the treatment of uterine fibroids grew to 45% in December 2021, six months following launchEstimated 11,000 cumulative patients treated with ORGOVYX through December 2021; Approximately 1,800 treatment centers have prescribed ORGOVYX since launchEstimated 1

BASEL, Switzerland, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE:MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and conference call to discuss corporate updates and financial results for its third fiscal quarter 2021, ended December 31, 2021. The webcast and conference call will be held at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time on January 26, 2022. Investors and the general public may access a live webcast of the call by visiting the investor relations page of Myovant's website at investors.myovant.com. Institutional investors and analysts may also participate in the conference call by dialing 1-8

Second fiscal quarter 2021 total revenues of $77.9 million; net product revenue from U.S. sales of ORGOVYX® of $18.7 million and MYFEMBREE® of $0.6 millionEstimated 8,000 cumulative patients treated with ORGOVYX through September 2021, including patients on commercial and free drug; Approximately 600 cumulative patients treated with MYFEMBREE through September 2021 including patients on commercial drug and free drug programs, excluding patients utilizing product samplesMYFEMBREE supplemental New Drug Application for the management of moderate to severe pain associated with endometriosis accepted for review by FDA in September 2021; FDA target action date is May 6, 2022RYEQO® approved in the

BASEL, Switzerland, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE:MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and conference call to discuss corporate updates and financial results for its second fiscal quarter 2021, ended September 30, 2021. The webcast and conference call will be held at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time on October 26, 2021. Investors and the general public may access a live webcast of the call by visiting the investor relations page of Myovant's website at investors.myovant.com. Institutional investors and analysts may also participate in the conference call by dialing 1-8

First fiscal quarter 2021 total revenues of $41.1 million; net product revenue from U.S. sales of ORGOVYX® of $10.5 million and MYFEMBREE® of $1.1 millionMYFEMBREE approved by the U.S. FDA in May 2021 as the first and only once-daily oral treatment for the management of heavy menstrual bleeding associated with uterine fibroids; FDA approval triggered a $100.0 million milestone payment from Pfizer received in July 2021RYEQO® approved by the European Commission in July 2021 for the treatment of women with uterine fibroids; Gedeon Richter will commercialize RYEQO in Europe; approval triggered a $15.0 million milestone payment from Gedeon Richter, expected to be received in second fiscal quarter